CHELMSFORD, Mass.--(BUSINESS WIRE)--ZOLL® Medical Corporation, an Asahi Kasei Group Company that manufactures medical devices and related software solutions, announced today that the ZOLL AED 3® defibrillator received premarket approval (PMA) by the FDA for use by lay rescuers.
“ZOLL is committed to supporting the public with all emergency preparedness needs during this COVID-19 pandemic and every day,” said Elijah A. White, President of ZOLL Resuscitation. “This next generation AED enhances ZOLL’s portfolio of top-of-the-line defibrillators by continuing to deliver real-time CPR feedback and providing even better support for our public access and professional customers.”
“At ZOLL, our mission is to provide intuitive and intelligent AEDs in every public space around the world and to enable bystanders to act quickly, appropriately, and with confidence in sudden cardiac arrest emergencies,” Mr. White added.
Designed for Unexpected Heroes™
ZOLL AED 3 continues ZOLL’s tradition of providing best-in-class AEDs to help improve outcomes from sudden cardiac arrest (SCA) by removing the guesswork for bystanders and giving them the confidence to respond.
High-quality CPR is the primary component in influencing survival from cardiac arrest.1 While only 50% of SCA victims will initially need a shock, nearly all will require CPR to increase the flow of blood to the heart and brain. The enhanced Real CPR Help® on the ZOLL AED 3 defibrillator provides unexpected heroes the confidence and knowledge needed to provide high-quality CPR when it matters most.
ZOLL AED 3 uses proven Real CPR Help technology with integrated, real-time feedback to help deliver Guideline-compliant CPR. Enhanced Real CPR Help offers industry-firsts such as a full-color display with vivid rescue images, a CPR cycle timer, and a large, color bar gauge that shows CPR compression depth. A calm voice tells rescuers to pause when it completes a heart analysis and alerts them if a shock is needed or if CPR should be resumed.
“The latest guidelines from resuscitation councils worldwide are clear: Successful defibrillation must be supported by high-quality CPR,” Mr. White said. “Every design choice in the ZOLL AED 3 had user confidence and high-quality CPR in mind.”
Integrated Pediatric Rescue
The ZOLL AED 3 defibrillator can treat adult and pediatric patients with a single CPR Uni-padz® electrode. To treat a child, rescuers use the same set of pads and simply activate child mode. ZOLL’s introduction of the world’s first 5-year universal CPR electrode not only provides enhanced ease of use, but it further improves the total cost of ownership by eliminating the need to purchase separate electrode pads for adults and children.
“This device sets a new industry standard, especially where high-quality CPR and the treatment of young people are concerned,” Mr. White explained.
Cloud connectivity enables automatic reporting of device status, giving rescuers the confidence of knowing the AED is ready in an emergency. WiFi also provides the ability to quickly access and transmit cardiac arrest event data to medical professionals.
More information about the ZOLL AED 3 defibrillator can found be at www.zoll.com/public-aed-3
About Sudden Cardiac Arrest (SCA)
SCA is an abrupt disruption of the heart’s function, which causes a lack of blood flow to vital organs. It is the leading cause of unexpected death in the world and strikes without warning.
About ZOLL Medical Corporation
ZOLL Medical Corporation, an Asahi Kasei Group Company, develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, supersaturated oxygen therapy, therapeutic temperature management, and ventilation, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, as well as lay rescuers, treat victims needing resuscitation and acute critical care. For more information, visit www.zoll.com.
About Asahi Kasei
The Asahi Kasei Group contributes to life and living for people around the world. Since its foundation in 1922 with ammonia and cellulose fiber business, Asahi Kasei has consistently grown through the proactive transformation of its business portfolio to meet the evolving needs of every age. With more than 40,000 employees around the world, the company contributes to sustainable society by providing solutions to the world’s challenges through its three business sectors of Material, Homes, and Health Care. Its health care operations include devices and systems for acute critical care, dialysis, therapeutic apheresis, transfusion, and manufacture of biotherapeutics, as well as pharmaceuticals and diagnostic reagents. For more information, visit www.asahi-kasei.com.
1Meaney PA, et al. Circulation. 2013 Jul 23;128(4):417–35.
Copyright © 2020 ZOLL Medical Corporation. Designed for Unexpected Heroes, Real CPR Help, Uni-padz, ZOLL, and ZOLL AED 3 are trademarks or registered trademarks of ZOLL Medical Corporation in the United States and/or other countries. Asahi Kasei is a registered trademark of Asahi Kasei Corporation. All other trademarks are the property of their respective owners.